Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse

Simple item page
dc.citation.articleNumber1800133en_US
dc.citation.issueNumber4en_US
dc.citation.journalTitlePROTEOMICS – Clinical Applicationsen_US
dc.citation.volumeNumber13en_US
dc.contributor.authorHoff, Fieke W.en_US
dc.contributor.authorHu, Chenyue W.en_US
dc.contributor.authorQutub, Amina A.en_US
dc.contributor.authorQiu, Yihuaen_US
dc.contributor.authorHornbaker, Marisa J.en_US
dc.contributor.authorBueso‐Ramos, Carlosen_US
dc.contributor.authorAbbas, Hussein A.en_US
dc.contributor.authorPost, Sean M.en_US
dc.contributor.authorBont, Eveline S.J.M. deen_US
dc.contributor.authorKornblau, Steven M.en_US
dc.date.accessioned2020-02-14T16:39:36Zen_US
dc.date.available2020-02-14T16:39:36Zen_US
dc.date.issued2019en_US
dc.description.abstractPurpose: Acute promyelocytic leukemia (APL) is the most prognostically favorable subtype of Acute myeloid leukemia (AML). Defining the features that allow identification of APL patients likely to relapse after therapy remains challenging. Experimental Design: Proteomic profiling is performed on 20 newly diagnosed APL, 205 non‐APL AML, and 10 normal CD34+ samples using Reverse Phase Protein Arrays probed with 230 antibodies. Results: Comparison between APL and non‐APL AML samples identifies 8.3% of the proteins to be differentially expressed. Proteins higher expressed in APL are involved in the pro‐apoptotic pathways or are linked to higher proliferation. The “MetaGalaxy” approach that considers proteins in relation to other assayed proteins stratifies the APL patients into two protein signatures. All of the relapse patients (n = 4/4) are in protein signature 2 (S2). Comparison of proteins between the signatures shows significant differences in relative expression for 38 proteins. Protein expression summary plots suggest less translational activity in combination with a less proliferative character for S2 compared to signature 1. Conclusions and Clinical Relevance: This study provides a potential proteomic‐based classification of APL patients that may be useful for risk stratification and therapeutic guidance. Validation in a larger independent cohort is required.en_US
dc.identifier.citationHoff, Fieke W., Hu, Chenyue W., Qutub, Amina A., et al.. "Proteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapse." <i>PROTEOMICS – Clinical Applications,</i> 13, no. 4 (2019) Wiley: https://doi.org/10.1002/prca.201800133.en_US
dc.identifier.digitalHoff_et_al-2019en_US
dc.identifier.doihttps://doi.org/10.1002/prca.201800133en_US
dc.identifier.urihttps://hdl.handle.net/1911/108034en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleProteomic Profiling of Acute Promyelocytic Leukemia Identifies Two Protein Signatures Associated with Relapseen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hoff_et_al-2019.pdf
Size:
1.63 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications